

**Joint Psychopharmacologic Drugs Advisory Committee (PDAC) and  
Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting  
October 8, 2020  
Pre-recorded Presentations**

Both the Food and Drug Administration (FDA) and Arbor Pharmaceuticals, LLC have prepared prerecorded presentations for the October 8, 2020, joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. These prerecorded presentations will be viewed by the committee prior to the meeting and **will not be replayed on meeting day.**

The recordings of the presentations can be found at the following addresses:

**FDA Presentations (listed in viewing order):**

1. Stimulant Use and Nonmedical Use by Joseph Shearer, PhD, MPH:  
<https://collaboration.fda.gov/paoj369g2av6/>
2. In Vitro Studies of Proposed Abuse-Deterrent Properties, NDA 211179 AR19 (amphetamine sulfate) capsules by Andrei Ponta, Ph.D.: <https://collaboration.fda.gov/p46ruxa81j8v/>
3. Evaluation of the Purported Abuse-Deterrent Properties of AR19 by Shalini Bansil, M.D.:  
<https://collaboration.fda.gov/pzw8bah9kkwf/>
4. Nonclinical Safety Assessment of AR19 Capsule Excipients by Shiny V. Mathew, PhD, DABT:  
<https://collaboration.fda.gov/p5pyhmx4xv68/>

**Arbor Pharmaceuticals, LLC (listed in viewing order):**

1. AR19 (amphetamine sulfate) Manipulation-Resistant, Immediate-Release Capsules for the Treatment of ADHD by Arbor Pharmaceuticals (1 of 2):  
<https://collaboration.fda.gov/pc1d43maeamj/>
2. AR19 (amphetamine sulfate) Manipulation-Resistant, Immediate-Release Capsules for the Treatment of ADHD by Arbor Pharmaceuticals (2 of 2):  
<https://collaboration.fda.gov/ph0dfks70h13/>

Your internet browser may require a plugin to playback these presentations. If your browser does not already have it installed, you may be prompted to download and install it.

The slides and transcripts of these pre-recorded presentations can be found at:

<https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-and-meeting-materials-information-october-8-2020-joint-meeting-psychopharmacologic>